Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Gastroenterology
Disease Category: Ulcerative Colitis
Trial Information
M06-826 - A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects with Moderately to Severely Active Ulcerative Colitis.
The purpose of this study is to evaluate the safety and effectiveness of two dosing groups of adakimumab for treatment of moderately to severely active colitis.
Patient Inclusion Criteria:
- Be at least 18 years of age
- Currently experiencing moderately to severely active ulcerative colitis
- Be willing to have up to three endoscopies
Patient Exclusion Criteria: Any surgery or procedure performed for ulcerative colitis
Carolinas Research Associates
16633 Birkdale Commons Pkwy.
Huntersville, NC 28028
Phone: 704-366-3001
EMail: contact@carolinasresearch.com
View Google Map
Research Center Information: Carolinas Research Associates
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
